NovalGen Enters Strategic Partnership with HALIX B.V. to Manufacture Clinical Trial Materials
NovalGen Ltd. (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies and HALIX B.V. (“HALIX”), a contract development and manufacturing organisation, today
announced a strategic partnership. Within the scope of this
partnership, HALIX will provide manufacturing of clinical supply of
NovalGen’s therapies.
More info >> |